On February 9th, the Hong Kong stock market saw increased volatility, with the biotechnology sector showing mixed performances. InSilico Medicine (03696.HK) saw a significant surge in its stock price in the afternoon. As of 14:34, the stock was priced at HKD 68.45, a 10.14% increase from the previous day's closing price of HKD 62.15. The stock briefly reached a high of HKD 69.00, hitting a recent peak.

（图源：uSMART HK app）

MEN2501 Advances to Key Milestone, Continued Value Realization from Partnerships

The main factor driving the stock price surge is the latest progress in the company’s AI drug pipeline. InSilico Medicine’s collaboration with Menarini Group on the candidate drug MEN2501 reached a new milestone. After completing the first patient dosing in the Phase I clinical trial, a milestone payment of approximately HKD 39 million was triggered. Previously, this project had brought InSilico Medicine over HKD 20 million in milestone payments during the development and regulatory phases. This payment signals the official transition of the project into the clinical execution stage and further validates the company's ability to generate consistent cash flow through clinical progress in its external partnerships.

AI-Generated Molecule Enters Human Testing Phase, Differentiated Advantage Emerges

Technically, MEN2501 is a small molecule inhibitor targeting KIF18A, primarily for the treatment of solid tumors associated with chromosomal instability. The molecule was designed and optimized using InSilico Medicine’s generative AI platform, showcasing the company’s systematic capabilities in molecular generation, screening, and optimization. As the project progresses to human clinical trials, market attention is shifting from whether AI can design molecules to whether it can continuously generate effective drug candidates in real-world clinical settings. The advancement of MEN2501 is seen as an important step for AI-generated molecules in their transition to actual medical applications.

Industry View Gains Traction, AIDD Platform's Capabilities Recognized by Market

From an industry perspective, the market generally believes that InSilico Medicine has established a relatively leading technological system in the AIDD (AI-driven drug discovery) field. The company has developed a replicable execution framework for chemical modeling, enabling the continuous output of candidate molecules across multiple projects, rather than being limited to a single pipeline. As some projects progress to human clinical stages, the validation path of biological models in real-world applications is becoming clearer, providing more solid support for the platform’s long-term value. In the context of global pharmaceutical companies accelerating the adoption of AI tools to enhance research and development efficiency, the industry is entering a broader phase of adopting AIDD technology. Platform companies with a first-mover advantage are expected to continue releasing growth potential as the industry trend deepens.

Market Interpretation: AI Drug Discovery Shifts from Concept-Driven to Result-Oriented

Overall, InSilico Medicine’s recent stock movement reflects the market’s reassessment of the commercialization pace of AI drug discovery. In the biotechnology sector, which faces long research and development cycles and increasing demands for certainty, platform companies that can continue to deliver partnership value through clinical milestones are gradually gaining more attention. As more AI-generated molecules enter clinical validation stages, the valuation logic for AI drug discovery is shifting from a technology narrative to a result-oriented phase, with a focus on project progress and cash flow capabilities.

How to Buy InSilico Medicine via on uSMART

After logging into the uSMART HK app, click the “Search” button in the top-right corner of the page, enter the ticker code (03696.HK), and navigate to the details page to view transaction details and historical trends. Click the “Trade” button in the bottom-right corner, select the trade type, and submit your order after filling in the transaction conditions.

(Image Source: uSMART HK app)